Canaccord Genuity Hires Harrison Wehner as Managing Director; Continues Building Global Life Sciences Practice
08 November 2012
NEW YORK, November 8, 2012 – Canaccord Genuity is pleased to announce the continued expansion of its Life Sciences practice, adding senior investment banker, Harrison Wehner to its global team. Harrison joins Canaccord Genuity as a Managing Director focused on biotechnology and specialty pharmaceuticals and will be based at the firm’s Boston office.
Over the past several months, Canaccord Genuity has significantly expanded its global Life Sciences practice with additions in the UK, Australia and the US. “We are very pleased to add Harrison’s talent and experience to our growing Life Sciences practice,” said Jeff Barlow, Managing Director and Head of US Investment Banking. “This is clearly a very interesting time in emerging therapeutics. We believe we have the team in place and expertise to play an increasingly active role in assisting companies in this sector with their financing and financial advisory needs.”
Harrison Wehner joins Canaccord Genuity from Citigroup where he served as a Managing Director in the Global Healthcare Group in New York and London. Prior to Citigroup, Mr. Wehner held positions at UBS Investment Bank in London and UBS Warburg and PaineWebber in New York. Harrison has 17 years of experience in initiating and executing mergers, acquisitions and securities offerings for biotechnology and technology companies.
Harrison received an MBA from the Ross School of Business at the University of Michigan and a BA from the College of William and Mary.
With the addition of Harrison, Canaccord Genuity’s global Life Sciences team consists of fifteen senior investment bankers located in five geographies: the US, Canada, UK, Australia and Asia. This banking team, combined with eight senior analysts and a specialized sales force in the sector, make Canaccord Genuity one of the leading investment banks focused on Life Science growth companies.
Back to Listing